Cortechs.ai | A word from the CEO: 2016 in review

A word from the CEO: 2016 in review

2016 Year End Review.png2016 was a very eventful year for Cortechs.ai! We continued to strengthen and build on the foundation we laid during 2014 and 2015. During the year, we experienced remarkable growth of our products, added many significant new customers, expanded into Europe and continued to develop our strategic business partnerships.

It is always exciting to watch hospitals, universities, radiology centers, clinical and research practices and military hospitals realize the importance and value of using quantitative imaging for the assessment of neurological disorders. During 2016, we were thrilled to see more neurologists, radiologists and neuroradiologists wholeheartedly support and champion NeuroQuant as the most proven and most accurate quantitative brain MR imaging solution to help them in their assessment of a variety of clinical disciplines, from dementia, to epilepsy, multiple sclerosis, traumatic brain injuries and brain development.

In 2016, we were delighted to introduce two highly anticipated NeuroQuant product enhancement platforms: PETQuant and LesionQuant.

  • PETQuant, a research-only tool, co-registers 3D T1 MRI and PET imaging to provide post-acquisition analysis of PET brain studies to quantify subregional tracer binding in native patient brain space.
  • LesionQuant, a NeuroQuant product, for FLAIR lesion identification, segmentation, quantification and visualization. This significant enhancement to NeuroQuant ready for clinical use and is intended to aid physicians in disease progression and monitoring of Multiple Sclerosis by combining information from 2D or 3D FLAIR and 3D T1 MR images, providing lesion and brain structure quantification in a completely automated and optimized easy-to-read report.

Additionally in 2016, we were pleased to receive Health Canada/Santé Canada medical device license to market and distribute NeuroQuant in Canada, as well as, delighted to announce three new strategic collaborations with Olea Medical, GE Healthcare’s Health Cloud and Philips Intellispace Portal 9.0. We were also happy to share that NeuroQuant is now compatible with Hitachi and Toshiba scanners. Finally, we were very proud to be recognized as leading and promising startup for innovation and technology in the Red Herring North America Awards. The 2016 Year End Review Infographic provides an overall picture of 2016’s amazing developments and accomplishments.

As you can see the team at Cortechs.ai has been extremely busy ensuring that our products continue to be the paramhttps://blog.cortechs.ai/wp-content/uploads/2017/02/343740/2016%20Year%20End%20Review.pdf?t=1486616743416ount solution for the assessment of neurological conditions and help enhance the quality of patient care. As always, we welcome feedback and ideas for improvement from anybody who would like to share it with us.

2016 was an incredibly exceptional year, and we are thrilled to share many more exciting developments during 2017! Stay tuned!

Sincerely,

Guri Stark
CEO, Cortechs.ai

Cortechs.ai | A word from the CEO: 2016 in review

More Resources

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.
Scroll to Top